Publications
View AllA randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...
Institution Info
- Type
- healthcare
- Country
- US
- Publications
- 2
- Citations
- 1,622
External Links
Identifiers
- ROR
- https://ror.org/00j1j3213